The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 07, 2025
Filed:
Jun. 21, 2022
Five Prime Therapeutics, Inc., Thousand Oaks, CA (US);
Bristol-myers Squibb Company, Princeton, NJ (US);
Xiao Min Schebye, San Carlos, CA (US);
Diana Yuhui Chen, San Francisco, CA (US);
Andrew Rankin, Redwood City, CA (US);
Xiaodi Deng, San Mateo, CA (US);
Joseph Toth, Belmont, MA (US);
Linda Liang, Mountain View, CA (US);
Michelle Minhua Han, Piedmont, CA (US);
Christine Bee, San Francisco, CA (US);
Hong-An Truong, San Francisco, CA (US);
Mark J. Selby, San Francisco, CA (US);
Nils Lonberg, Woodside, CA (US);
Guodong Chen, East Brunswick, NJ (US);
Richard Y. Huang, Bridgewater, NJ (US);
Ekaterina G. Deyanova, Lawrenceville, NJ (US);
Alan J. Korman, Piedmont, CA (US);
Five Prime Therapeutics, Inc., Thousand Oaks, CA (US);
Bristol-Myers Squibb Company, Princeton, NJ (US);
Abstract
The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.